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Constitutive Expression and Regulated Release
of the Transmembrane Chemokine CXCL16 in Human
and Murine Skin
Felix Scholz1, Alexander Schulte2, Frederic Adamski2, Christian Hundhausen2, Jens Mittag3,
Agatha Schwarz1, Marie-Luise Kruse4, Ehrhardt Proksch1 and Andreas Ludwig5
The CXC-chemokine ligand 16 (CXCL16) is expressed as a transmembrane adhesion molecule and can be
released as a chemoattractant. Both functions are carried out by binding of CXCL16 to its receptor, CXC-
chemokine receptor 6 (CXCR6). We here provide early evidence that CXCL16 is expressed in situ by epidermal
keratinocytes of normal skin on messenger RNA and protein level and released into the wound exudate upon
injury. Cultured human and murine keratinocyte cell lines (HaCaT and PAM212, respectively) as well as primary
keratinocyte cultures constitutively express transmembrane CXCL16 on the cell surface. Soluble CXCL16 is
released by its limited proteolytic cleavage involving the disintegrin-like metalloproteinase (ADAM)10 but not
the closely related ADAM17, as shown by specific inhibitors and small-interfering RNA knockdown
experiments. This shedding of CXCL16 is reduced by serum starvation but enhanced by cell stimulation with
ionomycin or by UVB irradiation. Soluble CXCL16 from keratinocytes was shown to bind and activate CXCR6,
and marked expression of this receptor was found on a subpopulation of T cells in the dermis. Thus, CXCL16 is
constitutively expressed on the surface of human epidermal keratinocytes, released upon cell activation or
photodamage and may then target CXCR6-expressing T cells in the dermis.
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INTRODUCTION
Chemokines play an important role as paracrine and
autocrine mediators in healthy and diseased skin where they
have been implicated in homeostatic and inflammatory
processes, and in the pathology of skin tumors. They function
as mediators of constitutive cell trafficking, promote inflam-
matory cell recruitment, and in some cases may control cell
proliferation and wound healing (Caux et al., 2000; Gillitzer
and Goebeler, 2001; Payne and Cornelius, 2002; Homey and
Bunemann, 2004). Most chemokines are soluble polypep-
tides of about 10 kDa either expressed and secreted
constitutively or released upon cell activation (Rossi and
Zlotnik, 2000; Rot and von Andrian, 2004). However, there
are two exceptional chemokines that are expressed as type I
transmembrane molecules, the CX3C-chemokine ligand
1/Fractalkine, and the CXC-chemokine ligand 16 (CXCL16)
(Bazan et al., 1997; Matloubian et al., 2000). These
molecules consist of a short cytoplasmatic tail, a single
membrane spanning a- helix, an extracellular, highly
glycosylated, mucine-like stalk and a globular, 10 kDa
chemokine domain at the N-terminus.
Different biological activities have been attributed to
CXCL16. As a surface-expressed molecule CXCL16 functions
as a scavenger receptor for oxidized low-density lipoprotein
(Shimaoka et al., 2000). In addition, surface-expressed
CXCL16 is capable of binding to its receptor CXC-chemokine
receptor 6 (CXCR6) expressed on leukocytes and thereby
establishes firm cell to cell contact (Shimaoka et al., 2004).
However, CXCL16 is not exclusively expressed on the cell
surface. It is also found as soluble molecule that is
constitutively generated by proteolytic cleavage of its
transmembrane variant, a process called shedding. In
fibroblasts and endothelial cells the disintegrin-like metallo-
proteinase (ADAM)10 has been implicated in constitutive
shedding of CXCL16 (Abel et al., 2004; Gough et al., 2004).
CXCL16 cleavage can be further enhanced by activation with
phorbol-12-myristate-13-acetate, which is independent of
ADAM10 but rather involves the related metalloproteinase
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ADAM17 (Abel et al., 2004; Ludwig et al., 2005b). Shedding
results in the release of soluble CXCL16 which then functions
as a chemoattractant for CXCR6-expressing cells such as
T-cell subtypes and bone marrow plasma cells (Matloubian
et al., 2000; Nakayama et al., 2003; Geissmann et al., 2005).
CXCL16 expression has first been reported for antigen-
presenting cells (Matloubian et al., 2000; Shimaoka et al.,
2000; Wilbanks et al., 2001) and was subsequently detected
in cytokine-stimulated endothelial cells, smooth muscle cells
(Abel et al., 2004), and in transformed glial cells (Ludwig
et al., 2005b). The chemokine and its receptor CXCR6 have
been found in inflamed vasculature (Minami et al., 2001),
liver (Geissmann et al., 2005), intestine (Hase et al., 2006),
lung (Morgan et al., 2005), rheumatoid joints (van der Voort
et al., 2005), and brain (Ludwig et al., 2005b), where they
have been implicated in disease processes such as acute and
chronic inflammation and tumor development. Nothing is
known, however, about the expression and function of both
molecules in the skin.
Here we provide first in vivo and in vitro evidence for the
constitutive expression of CXCL16 in epidermal keratinocytes
and its regulation by ADAM. We further demonstrate the
chemokine’s activity on its receptor CXCR6, which we could
localize to the dermis of healthy skin.
RESULTS
CXCL16 is expressed in human and murine skin
Expression of CXCL16 was investigated in paraform-fixed
paraffin sections of healthy human skin using a purified
polyclonal rabbit antibody directed against the chemokine
domain of human CXCL16. This antibody had been success-
fully used in several other studies to demonstrate the
expression of CXCL16 in situ. By chromogenic labeling the
antibody showed strong binding to keratinocytes throughout
the nucleated epidermal layers but not to cells of the dermal
layer or to the stratum corneum. (Figure 1a). This binding was
also seen using a polyclonal goat antibody to human CXCL16
(not shown) but neither with goat nor rabbit isotype control
antibodies (Figure 1c). As described previously for endothe-
lial cells in the brain (Ludwig et al., 2005b) CXCL16 was also
found on small blood vessels within the skin (Figure 1d). In
addition, a few distinct cells within the dermis were also
CXCL16 positive. But compared to the over all dermal
staining, the signal for CXCL16 in the epidermal layer was
more intense and therefore keratinocytes appear to be the
major source of this chemokine in healthy skin.
We next asked whether the metalloproteinase ADAM10
that has been implicated in cleavage of CXCL16 in fibroblasts
and endothelial cells is also expressed in human skin. We
found strong expression of the protease in the epidermal layer
(Figure 1b). Therefore we propose that CXCL16 and ADAM10
interact in human skin, which may lead to the cleavage and
release of soluble CXCL16.
We then investigated freshly prepared skin of healthy mice
for the presence of CXCL16 messenger RNA (mRNA). In situ
hybridization demonstrated a signal for CXCL16 mRNA in the
epidermal layer of murine skin (Figure 2a) and within the
dermis a specific signal was associated with blood vessels
(data not shown). To investigate the release of soluble
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Figure 1. Expression of human CXCL16 in normal human skin. For
chromogenic staining of CXCL16 and ADAM10 in healthy human skin,
acetone-fixed sections were incubated with (a, d) rabbit anti-hCXCL16
(b) rabbit anti-ADAM10 or an irrelevant (c) rabbit IgG control antibody
followed by incubation with POD-coupled goat anti-rabbit IgG antibody,
enzymatic staining and counterstaining with hemalumn. In (a–c) epidermal
skin and in (d) dermal skin containing a blood vessel (bottom right) is shown.
Bar¼50 mm.
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Figure 2. In situ expression and in vivo-release of murine CXCL16.
(a) Paraformaldehyde-fixed fresh frozen sections of murine skin were incubated
with radioactively labeled antisense cRNA probes (as) for mCXCL16 and sense-
controls (s), respectively. Hybridized cRNA probes were subsequently
visualized by autoradiography. Bar¼20mm. (b) Wound fluid from injured mice
was collected every 24hours over a period of 15 days, cleared by centrifugation
and subsequently analyzed for the presence of CXCL16 by an ELISA specific for
mCXCL16. Data are given as mean and SD (n¼5). Statistically significant
release of mCXCL16 (Po0.05) is indicated by asterisks.
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CXCL16 in the murine skin we next analyzed wound fluids of
injured mice for the presence of the chemokine. Quantifica-
tion of mCXCL16 by ELISA revealed that CXCL16 was present
in the cell-free wound fluid already within the first day after
injury. The release of CXCL16 was maximal after 3–5 days,
afterwards decreasing gradually to almost background levels
(Figure 2b).
CXCL16 is constitutively expressed and released by human
and murine keratinocyte cell lines
In vitro experiments were performed to further investigate the
expression of CXCL16 by keratinocytes. Cultured human
HaCaT cells and murine PAM212 cells, both representing
well-established keratinocyte cell lines, were analyzed for
surface expression of CXCL16 by flow cytometry. Using
antibodies directed against human or murine CXCL16,
respectively, we were able to demonstrate surface expression
of human and murine CXCL16 on human HaCaT and on
murine PAM212 cells, respectively (Figure 3a and c). We
then investigated whether soluble CXCL16 would be released
by the cultured cell lines. Using different ELISAs for human
and murine CXCL16, respectively, human HaCaT as well as
murine PAM212 cells were found to release CXCL16 in a
time-dependent manner. Moreover, in the presence of a
broad-spectrum metalloproteinase inhibitor (marimastat) the
CXCL16 release of both cell lines was considerably reduced
suggesting that a metalloproteinase activity is involved in this
process (Figure 3b and d).
To confirm CXCL16 expression by keratinocytes, we
prepared primary keratinocytes from human foreskin and
murine skin. Consistent with our previous observation the
primary cell cultures released soluble CXCL16 in a time-
dependent manner yielding concentrations of up to 1.2 ng/ml
after 4 hours of incubation as detected by an ELISA for murine
and human CXCL16, respectively (data not shown, compare
Figure 4c).
Release of CXCL16 from keratinocytes involves ADAM10
We next asked which metalloproteinase is responsible for the
release of CXCL16 from keratinocytes. In previous studies we
and others have demonstrated that ADAM10 and ADAM17
contribute to the release of transmembrane chemokines from
murine fibroblasts, endothelial cells, and CXCL16-transfected
ECV304 cells. As shown by Western blot analysis ADAM10
and ADAM17 are expressed in HaCaT cells and converted
into the mature, proteolytically active form (Figure 4a). To
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Figure 3. Surface expression and release of CXCL16 by cultured keratinocytes. (a) HaCaT cells were harvested and analyzed for CXCL16 surface expression
by flow cytometry using a purified rabbit anti-hCXCL16 antibody that was detected by a phycoerythrin-conjugated secondary antibody. The fluorescence
signal of the cells stained for hCXCL16 is shown in comparison to that of unstained cells or cells receiving an isotype control antibody. (b) HaCaT cells
were incubated in serum-free medium for different periods of time in the presence or absence of marimastat (5mM). Subsequently, conditioned media were
harvested and analyzed for released CXCL16 by a specific ELISA for hCXCL16. (c) PAM212 cells were incubated with a rat anti-mCXCL16 antibody, an isotype
control antibody, or left unstained. After incubation with a FITC-conjugated secondary antibody cells were analyzed by flow cytometry. (d) PAM212 cells
were incubated in serum-free medium for 4 hours in the presence or absence of marimastat (5 mM). Subsequently, released CXCL16 in the conditioned media
was determined by a specific ELISA for mCXCL16. Data are representative for three experiments and shown as mean and SD (n¼3). Asterisks indicate
statistically significant differences (Po0.05) between inhibitor-treated cells and untreated cells.
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investigate the contribution of ADAM10 and ADAM17 to
shedding of CXCL16 by keratinocytes we first employed two
previously described specific inhibitors, one of which
referred to as GI254023X, preferentially blocks ADAM10,
but not ADAM17, whereas the other, designated as
GW280264X, blocks both proteinases (Hundhausen et al.,
2003; Ludwig et al., 2005a). In cellular cleavage assays both
compounds dose dependently reduced the release of CXCL16
in HaCaT cells, CXCL16-transfected ECV304 cells, and in
primary human keratinocytes (Figure 4b–d). Moreover, the
reduced release was associated with an accumulation of
cellular CXCL16 in the three different cell types. Same results
were obtained in primary murine keratinocytes (data not
shown). These findings indicate that ADAM10 rather than
ADAM17 is involved in the constitutive cleavage of CXCL16
in keratinocytes.
To obtain further evidence for the role of ADAM10 in
CXCL16 cleavage we decided to downregulate the endogen-
ous expression of either ADAM10 or ADAM17 in primary
human keratinocytes by small-interfering RNA (siRNA)
technique. As demonstrated by RT-PCR for human ADAM10
or ADAM17 respectively, siRNA transfection led to specific
and concentration-dependent downregulation of either
metalloproteinase (Figure 5a and b). This effect was most
pronounced in the time period between 48 and 72 hours after
transfection and no side effect of ADAM10 siRNA on
ADAM17 expression and vice versa was observed (data not
shown). Next we performed release assays for endogenous
CXCL16 with siRNA-treated cells. In line with the inhibitor
studies, the downregulation of endogenous ADAM10 protein
expression after siRNA treatment (Figure 5c) turned out to
reduce the release of CXCL16 (Figure 5d) whereas the
targeting of ADAM17 had no effect (Figure 5e).
Release of soluble CXCL16 is upregulated upon cell activation
As cultured HaCaT cells release considerable amounts of
CXCL16 under normal cell culture conditions we tested
whether the growth medium by itself might upregulate
CXCL16 release. When the cells were incubated in medium
without serum for 4 or 8 hours, CXCL16 release was more
than 3-fold reduced compared to cells that received 2.5%
serum. This effect was not due to reduced cell proliferation, as
the total expression of CXCL16 in the cell lysates was not
significantly altered (data not shown). We then investigated a
number of different stimuli for their potential to modulate the
release of CXCL16. Cell stimulation with the proinflammatory
cytokines tumor necrosis factor-a, IFNg, or IL4 (each 10 ng/ml,
for 24 hours) did not affect protein expression of CXCL16 in
the cell lysates or in the corresponding conditioned media
(data not shown). This was in contrast to cultured endothelial
cells or monocytic cells (THP-1 cells) which do not express
CXCL16 constitutively but can be stimulated with IFNg to
express the chemokine on the protein level (Abel et al., 2004).
In the next experiment we addressed the short-term
regulation of CXCL16 shedding by treating serum-depleted
keratinocytes with 4-b-phorbol 12-myristate 13-acetate,
which is widely used to rapidly upregulate shedding events
that are predominantly mediated by ADAM17 (Garton et al.,
2001; Sahin et al., 2004). However, 4-b-phorbol 12-myristate
13-acetate treatment induced no significant increase in the
release of CXCL16, nor did it modulate cell-associated
CXCL16 (data not shown), suggesting that ADAM17 is not
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Figure 4. Effect of ADAM10/ADAM17-inhibitors on CXCL16-release from cultured keratinocytes. (a) Cell lysate of cultured HaCaT cells was investigated
for the presence of immature and processed forms of the metallproteinaseses ADAM10 and ADAM17. For Western blotting purified rabbit antibodies
against the C-terminus of ADAM10 and ADAM17, respectively were used. (b–d) (b) HaCaT cells (c) human primary keratinocytes, (d) WT-ECV304 and
CXCL16-ECV304 cells and were incubated for 4 hours in the presence or absence of 5mM GI254023X or GW280264X. Subsequently, conditioned media were
harvested and cell lysates were prepared. Released and cell-associated CXCL16 in media and lysates, respectively, was then quantified by ELISA.
Statistically significant differences (Po0.05) between inhibitor-treated cells and untreated cells are indicated by asterisks.
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the relevant CXCL16 sheddase. We then investigated
ionomycin as another potent inducer of shedding events
which are predominantly mediated by ADAM10 (Nagano
et al., 2004; Reiss et al., 2005). Ionomycin induced a rapid
time-dependent increase in CXCL16 release, which was
associated with a reduced content of the transmembrane
molecule in the cellular lysates as measured by ELISA (Figure
6a and b). This ionomycin-induced shedding was blocked by
the preferential ADAM10 inhibitor GI254023X suggesting
that ADAM10 is responsible for the ionomycin-induced
shedding of CXCL16 (Figure 6c).
In search of more physiological stimuli of shedding we
induced photodamage in keratinocytes by UVB irradiation.
Keratinocytes were serum starved for 16 hours and treated
with different dosages of UVB. Subsequently, cells were
further cultured in serum-free medium and after different
periods of time, released and cell-associated CXCL16 was
determined by ELISA. UVB radiation at a dosage of 10 mJ/cm2
lead to a more than 3-fold increase of soluble CXCL16 within
4 hours of incubation (Figure 7a). In the presence of
metalloproteinase inhibitors the release was blocked resulting
in an accumulation of the molecule in the cell lysates (Figure
7b and c). This effect was seen with both, the preferential
ADAM10- and the combined ADAM10/ADAM17-inhibitor
(GI254023X and GW280264X, respectively), suggesting that
ADAM10 inhibition is sufficient to suppress constitutive and
UVB-induced release of CXCL16.
The receptor CXCR6 is activated by keratinocyte-derived
CXCL16 and is expressed by distinct cells of the dermis
The biological activity of keratinocyte-derived CXCL16 was
determined by the use of CXCR6-transfected human embryo-
nic kidney (HEK)293 cells. As keratinocyte supernatants may
contain a number of stimuli potentially activating HEK293
cells, the cellular response to CXCL16 was directly measured
at the receptor level in terms of CXCR6-downregulation from
the cell surface. HaCaT-conditioned media were collected
and concentrated. The CXCL16 concentration was deter-
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Figure 5. Effect of ADAM10/ADAM17 downregulation by siRNA on CXCL16-release from kreatinocytes. Cultured keratinocytes prepared from human foreskin
were transfected with different heteroduplexed siRNA oligonucleotide constructs for downregulation of ADAM10 (A10-1, 2, 3) or ADAM17 (A17-1, 2, 3), an
irrelevant siRNA control or without siRNA. At 48 hours after transfection mRNA and protein was extracted. (a and b) The mRNA expression level of ADAM10
and ADAM17 was determined by real-time RT-PCR and expressed in relation to that of glyceraldehyde-3-phosphate dehydrogenase. (c) Lysates of
siRNA-transfected cells were analyzed for expression of the pro- and mature form of ADAM10 and controlled for b-actin content by Western blotting.
(d and e) For CXCL16 release experiments siRNA-treated cells were washed and incubated for 4 hours in fresh medium. (c and e) Subsequently, cells were
harvested for analysis of ADAM10 and ADAM17 mRNA expression and media were collected for quantification of released CXCL16 by ELISA. Data are
representative for three experiments and shown as mean and SD (n¼ 3). Asterisks indicate statistically significant differences (Po0.05) between cells
receiving specific siRNA and control cells treated with irrelevant siRNA.
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mined by ELISA and the conditioned medium was then added
to CXCR6-transfected HEK293 cells yielding a final concen-
tration of 18 ng/ml CXCL16. After 30 minutes of incubation
the expression level of CXCR6 at the cell surface was
investigated by flow cytometry. To verify that CXCR6 is
internalized upon ligand-engagement, cells were incubated
with recombinant human CXCL16 chemokine domain in
parallel. As expected, recombinant CXCL16 and the HaCaT-
conditioned medium profoundly reduced the surface expres-
sion of CXCR6 (Figure 8a). This effect was time- and
concentration-dependent (not shown) and could be comple-
tely prevented when the keratinocytes were stimulated with
either recombinant CXCL16 or HaCaT-conditioned medium
at 41C (Figure 8b), demonstrating the temperature depen-
dence of the internalization process. A purified rabbit
antibody against CXCL16 (5mg/ml), but not the respective
IgG control antibody was capable of blocking the receptor
internalization induced by either recombinant CXCL16 or
HaCaT-conditioned medium demonstrating that keratinocyte
derived CXCL16 was responsible for the internalization of its
receptor. (Figure 8c and d). Thus, CXCL16 produced by
keratinocytes was capable of binding and regulating its
receptor.
Finally, we questioned whether healthy human skin
contains CXCR6-expressing cells that could be target cells
for keratinocyte-derived CXCL16. We used a mAb against
human CXCR6 for immunofluorescence detection. A marked
expression of CXCR6 was found in a small number of distinct
cells in the papillary dermis (Figure 9a). Notably, CXCR6-
expressing cells were absent in the epidermis of healthy skin
and were therefore distinct from CXCL16-expressing epider-
mal keratinocytes (Figure 9b). This was consistent with our
finding that cultured keratinocytes release CXCL16 but do not
express CXCR6 at protein or mRNA level (data not shown).
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Double staining for CD3 and CD 68 surface markers revealed
that most CXCR6-positive cells belonged to the CD3-positive
T-cell lineage (Figure 9c). However, not all CD3-positive
cells were stained for CXCR6 suggesting that only a
subpopulation of T cells expresses CXCR6.
DISCUSSION
We here provide in vivo and in vitro evidence for the
expression and shedding of the transmembrane chemokine
CXCL16 in the skin. We show that CXCL16 is constitutively
expressed by epidermal keratinocytes of healthy human skin.
We found that CXCL16 is constantly released from the cell
surface of cultured keratinocytes by the activity of ADAM10.
This shedding is diminished upon depletion of growth factors,
but enhanced by ionomycin and UVB irradiation. We further
demonstrate that CXCL16 released from keratinocytes is
functionally active in terms of binding to CXCR6 and
inducing receptor internalization. CXCR6 is expressed in
healthy skin and could be located on distinct cells of the
papillary dermis. CXCL16 and CXCR6 are therefore expressed
in different compartments of healthy skin.
Keratinocytes have been identified as important producers
of chemokines in the skin (Caux et al., 2000; Gillitzer and
Goebeler, 2001; Homey and Bunemann, 2004). Notably,
most chemokines are expressed only upon stimulation of
keratinocytes. Bacterial products or proinflammatory cyto-
kines are major inducers of the so-called inflammatory
chemokines. Among these are T-helper-1 cell type chemo-
kines inducible by IFNg and tumor necrosis factor-a, and
T-helper-2 type chemokines inducible by IL4. In a number of
cell types including smooth muscle cells and endothelial
cells IFNg has been found to stimulate expression of CXCL9/
10/11, CX3C-chemokine ligand 1 and also CXCL16 (Abel
et al., 2004; Wuttge et al., 2004). In keratinocytes, IFNg
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Figure 8. Activity of keratinocyte-derived CXCL16 on CXCR6-transfected
HEK293 cells. CXCR6-expressing HEK293 cells were treated with
recombinant CXCL16 or concentrated HaCaT-conditioned (HaCaT-CM)
medium for 30 minutes at either (a) 371C or (b) 41C. In a separate experiment
recombinant CXCL16 or concentrated HaCaT-conditioned medium were
preincubated with a neutralizing antibody to (c) CXCL16 or an (d) isotype
control and then added to the CXCR6-expressing HEK293 cells for 30 minutes
at 371C. Subsequently, cells were assayed for CXCR6 surface expression using
a phycoerythrin-labeled mAb to CXCR6. As a control, WT-HEK293 cells
expressing no CXCR6 were stained in parallel. The mean intensity of the
fluorescence signal from CXCL16 or HaCaT-CM-treated cells was calculated
as percentage of that from untreated cells and is shown as insets. Data are
representative for three experiments.
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Figure 9. Immunfluorescence staining of human and murine skin for CXCR6.
Paraformaldehyde-fixed sections of healthy human paraffin-embedded skin
were incubated with (a) rabbit anti-hCXCR6 antibody or coincubated with
(b) rabbit anti-hCXCL16 and monoclonal mouse anti-hCXCR6 antibodies.
Bound antibodies were then detected with Cy2-coupled goat anti-rabbit IgG
or Cy3-coupled goat anti-mouse IgG, respectively. (c) Sections were
incubated with rabbit anti-hCD3 and mouse anti-hCXCR6 antibodies
followed by incubation with Cy2-coupled goat anti-rabbit IgG and
Cy3-coupled goat anti-mouse IgG and subsequently analyzed for
immunfluorescence indicating expression of CD3 (left), CXCR6 (right) or
both (middle). Bar¼ 20 mm.
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induces CX3C-chemokine ligand 1, CXCL10, and CXCL9
(Kaplan et al., 1987; Tensen et al., 1999; Sugaya et al., 2003),
but surprisingly, as we describe here IFNg does not induce
CXCL16. Instead, CXCL16 is constitutively expressed by
keratinocytes in situ and in vitro and the expression is not
further enhanced by cytokine stimulation. These findings
reveal that a pool of CXCL16 is constantly present in healthy
skin suggesting a function different from that of most other
chemokines that are absent in healthy skin with exception of
the homeostatic chemokine CXCL4 (Fedyk et al., 2001).
The metalloproteinase ADAM10 has been implicated in
the processing of CXCL16 in endothelial cells, fibroblasts,
and glioma cells (Abel et al., 2004; Gough et al., 2004;
Ludwig et al., 2005b). As we demonstrate here by the use of
previously described specific inhibitors (Ludwig et al.,
2005a), as well as siRNA knockdown experiments, this
metalloproteinase also is the major candidate for shedding
of CXCL16 in keratinocytes. Interestingly, 4-b-phorbol
12-myristate 13-acetate, which is known to induce several
ADAM17-mediated shedding processes, including that of
CX3C-chemokine ligand 1 (Garton et al., 2001), does not
enhance the release of CXCL16. However, shedding is
enhanced by ionomycin, which has been used previously
to upregulate ADAM10-mediated cleavage processes (Naga-
no et al., 2004; Reiss et al., 2005). Moreover, UVB
irradiation, within physiological doses also enhances the
release of CXCL16, a process that can be blocked by
ADAM10 inhibition. Taken together, these findings suggest
that ADAM10 is not only constitutively active but can be
further activated in response to cellular stress imposed by
ionomycin or UV radiation to release more CXCL16 from
keratinocytes.
Various biological activities have been attributed to
CXCL16. The transmembrane chemokine has been demon-
strated to function as a scavenger receptor on macrophages
mediating uptake of oxidized low-density lipoprotein in vitro
(Shimaoka et al., 2000). Additionally, it promotes the binding
and phagocytosis of bacteria (Shimaoka et al., 2003) by
macrophages. Thus, there is evidence that pathogenic
molecules may be recognized by CXCL16. Some chemo-
kines, including truncated forms of CTAPIII/CXCL7, exhibit
bactericidal activity (Krijgsveld et al., 2000). It therefore
remains to be elucidated whether CXCL16 might exert a
protective role in the skin as a component of the innate
defense system. On the other hand, CXCL16 is well known to
bind and activate the chemokine receptor CXCR6 (Matlou-
bian et al., 2000; Wilbanks et al., 2001). In healthy human
and murine skin we found CXCR6-immunoreactive cells in
the papillary dermis but not in the epidermal layer. Dermal
skin usually contains fibroblasts, endothelial cells, nerve
endings, mast cells, dendritic cells, and T lymphocytes even
in the absence of an immune response. Among these different
cell types, T-cell subsets and natural killer T-cells have been
described to express CXCR6 in various tissues including
peripheral blood (Sharron et al., 2000), Peyers’ patches (Hase
et al., 2006), rheumatoid joints (van der Voort et al., 2005),
and the liver (Geissmann et al., 2005). We here could
demonstrate the expression of CXCR6 on CD3-positive cells,
but importantly, within healthy skin not all CD3-positive cells
were stained for CXCR6. In a recent study, CXCR6 could also
be detected on isolated T-helper type 1 cells from human
healthy skin using flow cytometry (Clark et al., 2006).
Therefore, resident CXCR6 positive cells in the dermal skin
are very likely to represent a T lymphocyte subpopulation
and further investigation is required to define this T-cell
phenotype. Notably, the ligand CXCL16 is exclusively
located in the epidermis of healthy skin and therefore
unlikely to activate CXCR6 within the dermis. However, we
here provide evidence that soluble CXCL16 is released into
the wound fluid of injured skin in mice. We also show that
increased amounts of CXCL16 are released from keratino-
cytes in response to photodamage. It can be envisaged that
disruption of skin integrity induced by mechanical injury or
sunburn leads to infiltration of released CXCL16 into the
dermis where it will get in contact with CXCR6-positive cells
within the dermis and then cause the activation of these cells.
The CXCR6-positive cells could either migrate to the site of
injury or they could be stimulated to carry out further
mediatory functions that allow to coordinate an appropriate
response for skin repair. We therefore propose an instru-
mental role of proteolytic shedding by ADAM10 for the
function of the CXCL16/CXCR6 axis in skin.
MATERIALS AND METHODS
Cytokines, antibodies, and inhibitors
Recombinant human CXCL16 extracellular domain and chemokine
domain, recombinant human IFN-g, recombinant human tumor
necrosis factor-a, goat anti-human CXCL16 (hCXCL16) antibody, rat
anti-murine CXCL16 (mCXCL16) mAb (clone 142417), phycoery-
thrin-conjugated and unconjugated mouse anti-human CXCR6
(hCXCR6) mAb (clone 56811), and rat anti-murine CXCR6
(mCXCR6) mAb (clone 221002) were obtained from R&D Systems
(Wiesbaden, Germany). Unconjugated and biotinylated rabbit anti-
hCXCL16 antibody and goat anti-mCXCL16 antibody were from
PeproTech (London, UK). The rabbit antiserum B 42.1 against the
C-terminus of murine/human ADAM10 was kindly provided by
Dieter Hartmann (Leuven and Flanders Interuniversity, Belgium) and
characterized previously (Hartmann et al., 2002). The purified rabbit
antibody against the C-terminus of human ADAM17 was from
Chemicon (Chandlers Ford, UK). The rabbbit anti-human CD3
antibody was obtained from Dako (Hamburg, Germany). The
metalloproteinase inhibitors GW280264X ((2R,3S)-3-(Formyl-hydro-
xyamino)-2-(2-methyl-1-propyl) hexanoic acid [(1S)-5-benzyloxy-
carbamoylamino-1-(1,3-thiazol-2-ylcarbamoyl)-1-pentyl] amide)
and GI254023X ((2R,3S)-3-(Formyl-hydroxyamino)-2-(3-phenyl-1-
propyl) butanoic acid [(1S)-2,2-dimethyl-1-methylcarbamoyl-1-pro-
pyl] amide) were synthesized as described in US Patents US 6 172
064, US 6 191 150, and US 6 329 400. Marimastat was from
GlaxoSmithKline (Stevenage, UK) (Chapman et al., 2000). The
compounds were assayed for inhibition of recombinant human
ADAM17 and ADAM10 ectodomains as described (Hundhausen
et al., 2003; Ludwig et al., 2005a).
Immunohistochemistry
For hCXCL16 chromogenic staining, paraform-fixed sections of
normal, healthy human skin were incubated with 1% BSA in
www.jidonline.org 1451
F Scholz et al.
CXCL16 in Skin
Tris-buffered saline to block unspecific binding and incubated with
0.3% H2O2 to block endogenous peroxidase (POD) activity.
Sections were incubated with rabbit anti-hCXCL16 (250 ng/ml
PeproTech Inc., Rocky Hill, NJ), rabbit anti-ADAM10 (5 mg/ml,
Chemicon, Temecula, CA) or normal rabbit IgG in Tris-buffered
saline at 41C overnight. Bound antibody was detected with a POD-
conjugated goat anti-rabbit IgG (Dianova, Hamburg, Germany) and
chromogenic reagents (BioGenex, San Ramon, CA). Nuclei were
counterstained with hemalumn (Merk, Darmstadt, Germany).
For hCXCL16 indirect immunofluorescence staining, paraffin-
embedded human skin fixed in 8% formalin was used. Unspecific
antibody binding was blocked with 0.1% BSA (PAA Laboratories,
Linz, Austria) and 0.2% glycine in Tris-buffered saline. For blocking
of unspecific binding of antibodies to Fc-receptors, 2 ng/ml sheep
IgG Fc-fragments (Dianova) were added for 1 hour at room
temperature (RT). Human CXCL16 was detected with a purified
rabbit anti-hCXCL16 antibody (250 ng/ml, PeproTech). For detection
of human and murine CXCR6 a mouse mAb to hCXCR6 (2.5 mg/ml,
R&D Systems) or a rat mAb to mCXCR6 (1 mg/ml, R&D Systems) was
used, respectively. Sections were incubated overnight at 41C. For
fluorescent staining of T-cell sections were incubated with a rabbit
anti-human CD3 antibody (Dako) for 1 hour at RT. As secondary
reagents Cy2-coupled goat anti-rabbit-IgG, Cy3-coupled goat anti-
mouse-IgG and FITC-coupled goat anti-rat-IgG antibodies (Dianova)
were applied according to the manufacturers recommendations.
Nuclei were counterstained with bisbenzimide (Hoechst 33258) and
sections were analyzed by confocal laser scanning microscopy
(Zeiss, LSM 510 UV, Jena, Germany).
In situ hybridization
Radioactive-labeled RNA probes were generated by in vitro
transcription from a cDNA fragment corresponding to nt 632–965
of mCXCL16 (accession no. NM_023158) in a pGEM-T easy plasmid
(Promega, Mannheim, Germany) using (35S)-uridine triphosphate
and (35S)-cytidine triphosphate as labeled nucleotides. Probes were
diluted in hybridization buffer (50% formamide, 10% dextran
sulfate, 0.05% tRNA, 0.6 M NaCl, 10 mM Tris HCl pH 7.4, 1
Denhardt’s solution, 100 mg/ml sonicated salmon sperm DNA, 1 mM
EDTA, and 10 mM dithiothreitol) to a final concentration of
5 104 c.p.m./ml. Feshly prepared murine skin was embedded in
Tissue-Tek medium (Sakura Finetek, Torrance, CA) and frozen on dry
ice. Sections (25 mm) were cut on a cryostat (Leica, Bentheim,
Germany), thaw-mounted on silane-treated slides, fixed in a 4%
phosphate-buffered paraformaldehyde solution (pH 7.4) for 1 hour at
RT, rinsed with phosphate-buffered saline (PBS) and treated with
0.4% phosphate-buffered Triton  100 solution for 10 minutes. After
washing with PBS and water, tissue sections were incubated in 0.1 M
triethanolamine (pH 8) containing 0.25% (v/v) acetic anhydride for
10 minutes, rinsed several times with PBS, washed with increasing
ethanol concentrations, and air dried. After application of the
labeled cRNA probes, sections were incubated in a humid chamber
at 581C for 16 hours. After hybridization, sections were rinsed with
2 standard saline citrate (0.3 M NaCl, 0.03 M sodium citrate, pH
7.0), and treated with RNAse A (20 mg/ml), and RNAse T1 (1 U/ml) at
371C for 30 minutes. Successive washes followed at RT in 1 ,
0.5 , and 0.2 standard saline citrate for 20 minutes each and in
0.2 standard saline citrate at 651C for 1 hour. The tissue was then
dehydrated and sections were dipped in NTB2 (Kodak, Integra
Biosciences, Germany) nuclear emulsion and stored at 41C. After
exposure for 14 days, autoradiograms were developed. If required,
sections were counterstained with cresyl violet and then photo-
graphed under darkfield or brightfield illuminations. Sense probes
that were used to confirm the specificity of the hybridization did not
show any signal.
In vivo wounding
Five hairless mice (SKH-1, Charles River, Wilmington, MA) were
anaesthetized and wounded by excision of 200 mm2 skin on the right
flank. The animals were bandaged with Comfeel (Coloplast, Ham-
burg, Germany). To collect the exudates, wounds were washed every
day with 200ml PBS and then re-bandaged. The washing fluid was
then analyzed for presence of CXCL16 by ELISA as described below.
Tissue samples, preparation, and culture of keratinocytes
Primary human keratinocytes were prepared from foreskin as
described before (Harder et al., 2004). The medical ethical
committee of the Christian-Albrechts-University Kiel (D410/04)
approved all experiments with primary human keratinocytes. The
study was conducted according to the Declaration of Helsinki
Principles. Experiments were performed with written informed
consent of tissue donors. Cells were maintained in EpiLife medium
(Cascade Biologics, Portland, OR) containing EpiLife defined growth
supplement, 0.06 mM CaCl2, 100 U/ml Penicillin, 100mg/ml Strepto-
mycin (both from Gibco, Grand Island, NY). Cells were grown in
12-well plates and received fresh medium every second day.
Primary murine keratinocytes were prepared from 2 d old mice
(Balb/C, Charles River, Wilmington, MA). The skin was digested with
0.48 U/ml of dispase II (Roche Diagnostics, Mannheim, Germany) in
serum-free keratinocyte growth medium (Gibco) for 2.5 hours at RT.
The epidermis was mechanically separated from the dermis and
digested with Trypsin-EDTA solution (Invitrogen, Carlsbad, CA) for
10 minutes. The cells were passaged through a cellstrainer of 100 mm
mesh size (VWR International, Darmstadt, Germany) and digestion
was stopped with soybean-trypsin inhibitor (Sigma, Munich,
Germany, 1 mg/ml). After centrifugation at 1,200 g for 5 minutes
the cells were seeded on bovine collagen IV (Becton Dickinson,
Franklin Lakes, NJ) coated to 12-well plates (Becton Dickinson) and
grown in serum-free KSFM medium containing 100 mM CaCl2,
5mg/ml recombinant human epidermal growth factor, and 50 mg/ml
0.1 ng/ml bovine pituitary extract.
HEK293 cells, stably expressing hCXCR6 or hCXCL16 were
generated by transfection with hCXCR6- or hCXCL16-cDNA inserted
into the expression vector pcDNA3.1 and subsequent selection with
geneticin (500mg/ml, PAA Laboratories). Separate clones grown at
limiting dilution were harvested and analyzed for surface expression
of hCXCR6 and hCXCL16 by flow cytometry (see below).
The spontaneously transformed human keratinocyte cell line
HaCaT (From Dr Fusenig, DKFZ Heidelberg, Germany) and the
murine keratinocyte cell line PAM212 were cultured in DMEM and
Rosewell Park Memorial Institute 1640 medium, respectively, both
supplemented with 10% fetal bovine serum (PAA Laboratories).
Analysis of CXCL16 and CXCR6 surface expression by flow
cytometry
For flow cytometric analysis adherent cells were harvested by
scraping into ice-cold PBS containing 0.1% BSA, and washed once.
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To investigate human CXCL16 surface expression, cells were
resuspended in ice-cold PBS containing 0.1% BSA and
0.01%NaN3 at 3 105 cells/ml and incubated with purified rabbit
anti-hCXCL16 or rabbit IgG control (both diluted at 2 mg/ml in PBS
with 0.1%BSA and 0.01%NaN3) for 1 hour on ice. To analyze
mCXCL16 surface expression a monoclonal rat anti-mCXCL16 and a
respective isotype control (both at 3mg/ml) were used. After washing,
cells were incubated with secondary fluorescein-conjugated goat
F(ab0)2-antibody fragments against rabbit IgG (Dako) or phycoery-
thrin-conjugated goat F(ab0)2-fragments against rat IgG (Dianova),
respectively, for 1 hour on ice. To examine hCXCR6 surface
expression, an anti-hCXCR6 mAb directly coupled to phycoerythrin
and a respective isotype control antibody (both at 3 mg/ml) were
used. Cells were washed twice and suspended in ice-cold PBS
containing 2% paraformaldehyde (PFA, Roth, Karlsruhe, Germany).
The fluorescence signal of the labeled cells was then analyzed by
flow cytometry (FACScan, Becton Dickinson, Heidelberg, Germany)
and calculated as median fluorescence intensity of the cell
population. The specificity of the detection method was controlled
by the use of non-transfected HEK293 cells that showed no
fluorescence staining in contrast to that of hCXCR6- or hCXCL16-
transfected HEK293 cells.
CXCL16 release assays
Keratinocytes were grown until they reached 70–90% confluency,
washed with PBS, and 0.75 ml fetal calf serum-free medium with or
without metalloproteinase inhibitors was added. After 5 minutes, the
cells were stimulated with 4-b-phorbol 12-myristate 13-acetate,
ionomycin (both from Sigma) or left unstimulated for various periods
of time. The conditioned media were harvested, cleared by
centrifugation and a protease inhibitor cocktail (Complete, Roche
Diagnostics) was added according to the instructions of the
manufacturer. The cells were washed with ice-cold PBS and then
lysed in PBS containing proteinase inhibitors and 1% Triton X-100.
The lysates were then cleared by centrifugation at 10,000 g for
10 minutes. The amount of CXCL16 in the conditioned media and
cell lysates was analyzed by ELISA (see below).
UV irradiation
HaCaT cells were seeded in tissue culture dishes at a density of
2 105 cells/ml and grown to 70–90% confluency. Before UV
irradiation cells were serum-starved for 16 hours. Subsequently,
cells were washed with prewarmed PBS and exposed to UV light in
the presence of PBS. For UVB irradiation, six FS20 fluorescent lamps
were used (emission peak 313 nm, Philips, Eindhoven, Netherlands).
Immediately after UV treatment, PBS was replaced by serum-free
DMEM medium and the cells were further cultured for up to
24 hours. Control cells were subjected to the identical procedure
without UV exposure.
CXCL16 specific ELISA
The ELISA for human CXCL16 was carried out as described before
(Abel et al., 2004). In brief, goat anti-human CXCL16 (2mg/ml) was
coated to a microtiter plate (Microlon, Greiner, Frickenhausen,
Germany), followed by blocking with 0.05% Tween in PBS (PBS-T)
containing 2% BSA for 2 hours. The samples and a standard,
prepared as serial 1:2 dilutions of 6.25 ng/ml recombinant human
CXCL16 in PBS-T with 1% BSA, were added for 2 hours, followed by
2 hours incubation with 200 ng/ml biotinylated rabbit anti human
CXCL16 in PBS-T containing 1% BSA. After 1 hour incubation with
100 mU/ml streptavidin-POD conjugate (Roche Diagnostics) in PBS-
T with 1% BSA, the bound enzymatic activity was quantified using
chromogenic POD substrate (BM blue, Roche Diagnostics). The
specificity of the ELISA was demonstrated by its positive reaction
with lysates and conditioned media of CXCL16-transfected COS7
cells or ECV-304 cells as described previously (Abel et al., 2004).
The ELISA specific for murine CXCL16 was purchased from R&D
Systems and performed following the manufacturer’s instructions.
The ELISA reacted with lysates and supernatants of COS7 cells
transfected with murine CXCL16 but not with that of cells transfected
with human CXCL16 or empty vector (Abel et al., 2004).
siRNA
For downregulation of endogenous ADAM10/ADAM17 expression
in human keratinocytes the following duplexed RNA oligonucleo-
tides (Stealth RNAi) were used: ADAM10-construct 1, 50-UAC ACC
AGU CAU CUG GUA UUU CCU C-30; ADAM10 construct 2,
50-AAC AGU AGU CAU CAU GAU UCU GCU C-30 ADAM10-
construct 3, 50-AGA AUU AAC ACU CUC AGC AAC ACC A-30;
ADAM17-construct 1, 50-AUG AGU UGU AAC CAG GUC AGC
UUC C-30; ADAM17-construct 2, 50-AUA CAU GAC AUA UUU
CCC UCC CUG G 30; ADAM17-construct 3, 50-UAC UGU ACA
GGG CUU UCC UUU CCU C-30. As negative control unspecific
stealth RNA duplexes (Invitrogen) with low GC content were used.
For transfection human primary keratinocytes were grown to 60%
confluence in 12-well plates. The siRNA constructs were preincu-
bated with Lipofectamin 2000 (1ml/well, Invitrogen) for 20 minutes
at RT and then applied to the cells at final concentrations of 10, 20,
and 30 pM in 500ml EpiLife medium (Cascade Biologics) without
antibiotics. After 6 hours of incubation the medium was replaced and
the cells were further incubated for 48 or 72 hours. Subsequently,
efficiency of mRNA knockdown was measured by RT-PCR.
Conditioned media were harvested and analyzed for the presence
of released CXCL16 by ELISA.
RNA isolation, RT-PCR, and quantitative real-time RT-PCR
The cells were lysed in 1 ml TRIzol (Invitrogen) followed by
chloroform (Sigma-Aldrich, Munich, Germany) and isopropanol
(Sigma-Aldrich) precipitation as described by the manufacturer. RNA
quantity and quality were determined by photometry and gel
electrophoresis. RNA (2 mg) was digested with DNAse I (Fermentas,
St Leon-Rot, Germany) followed by reverse transcription with
Superscript II (Invitrogen). Quantitative real-time RT-PCR was
performed in a flourescence temperature cycler (LightCycler; Roche
Diagnostics) as described elsewhere (Harder et al., 2004). The
following primers were used: ADAM10, 50-TCC AC AGC CCA TTC
AGC AA-30 and 50-GCG TCT CAT GTG TCC CAT TTG-30; ADAM17
50-GAA GTG CCA GGA GGC GAT TA-30 and 50-CGG GCA CTC
ACT GCT ATT ACC 30; glyceraldehyde-3-phosphate dehydrogenase,
GA1 50-CCA GCC GAG CCA CAT CGC TC-30 GA2 50-ATG AGC
CCC AGC CTT CTC CAT-30 Reactions were performed in 10 ml
volumes containing 5 ml SYBR Premix Ex Taq (MoBiTec; Go¨ttingen,
Germany), 0.2 mM of each each primer and serial dilutions of cDNA.
Following denaturation at 951C for 30 s, a touch down PCR was run
with 45 cycles of 10 s denaturation at 951C, followed by 20 s
annealing from 661C down to 551C and 15 s amplification at 721C.
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To confirm specificity of the amplified DNA a melting curve was
determined at the end of each run by cooling down to 651C for 15 s
and heating slowly at 0.21C/s to 951C with continuous measurement
of the fluorescence. Standard curves were determined for each
primer pair with serial dilutions of cDNA. All samples were
quantified in relation to the expression of glyceraldehyde-3-
phosphate dehydrogenase. Results were expressed as ratio of target
gene and glyceraldehyde-3-phosphate dehydrogenase expression.
Western blot analysis of ADAM10 and ADAM17
Western blot analysis of endogenous ADAM10 and ADAM17 was
performed as described previously (Hundhausen et al., 2003). In
brief, the cells were washed with PBS and either directly lysed in
reducing SDS-sample buffer or used for simultaneous extraction of
proteins and mRNA (Macherey and Nagel, Du¨ren, Germany)
following the manufacturer’s recommendations. Samples were then
subjected to SDS-polyacrylamide gel electrophoresis under reducing
conditions using 10% Tris-glycine gels. Proteins were transferred
onto polyvinylidene difluoride membranes (Hybond-P, Amersham,
Freiburg, Germany) that were probed with dilutions of rabbit
antiserum against ADAM10 (1:10,000) or rabbit antiserum against
ADAM17 (1:1,000). Bound Ig was detected with POD-coupled goat
anti-rabbit Ig (Perbio, Bonn, Germany, diluted 1:10,000 in PBS-T)
and subsequent addition of enhanced chemiluminescence substrate
(ECLplus, Amersham). Signals were recorded using a luminescent
image analyzer (Fujifilm Image reader, LAS1000, Tokyo, Japan).
Equal loading and transfer of proteins to the membrane was
controlled by subsequent detection of b-actin using a specific
mAb, mAbcam 8226 (Abcam, Cambridge, UK) followed by POD-
coupled goat anti-mouse Ig (Perbio, diluted 1:10,000 in PBS-T).
Statistical analysis
Two populations of data were statistically analyzed using the
unpaired two tailed t-test and considered significantly different at
P-values smaller than 0.05.
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